L2 Bio Seeks Principal Investigators for Groundbreaking Crohn's Disease Trial

Strategic Insights -

L2 Bio, the leader in adipose-derived stem cell banking, is actively recruiting Principal Investigators for its recently FDA-approved Phase 2B clinical trial for Crohn's Disease. This study aims to investigate a novel intravenous delivery of adipose-derived stem cells (ADSCs) for the treatment of Crohn's Disease. The trial has the potential to significantly impact the lives of individuals suffering from Crohn's Disease, and L2 Bio is seeking qualified Principal Investigators to contribute to this pivotal clinical trial.

Key Takeaways:

  • L2 Bio is seeking Principal Investigators with experience in treating patients with Crohn's Disease, Inflammatory Bowel Disease (IBD), or related gastrointestinal conditions.
  • The company has an FDA-approved Investigational New Drug (IND) for its adipose-derived stem cell therapy and is now recruiting Principal Investigators for its Phase 2B clinical trial.
  • The trial will investigate the safety and efficacy of intravenous delivery of adipose-derived stem cells (ADSCs) for the treatment of Crohn's Disease.
  • Key qualifications for Principal Investigators include a Medical Doctor (MD) or Doctor of Osteopathic Medicine (DO) degree, demonstrated experience in the clinical management and treatment of patients with Crohn's Disease, and familiarity with clinical trial protocols and regulatory requirements.
  • Interested physicians are invited to submit their Curriculum Vitae (CV) and a brief paragraph detailing their experience with Crohn's Disease, IBD, or related conditions.
  • The trial has a high safety profile, with no chance of rejection or side effects from the cells themselves, and will involve a simple, virtually painless, 15-minute procedure.

Statistics:

  • Over 100 submissions, approvals, and clearances for L2 Bio's clients with the FDA over the past 20 plus years.
  • The Phase 2B clinical trial plans to recruit Principal Investigators who have experience in treating patients with Crohn's Disease, IBD, or related conditions.
  • The trial will investigate the safety and efficacy of intravenous delivery of adipose-derived stem cells (ADSCs) for the treatment of Crohn's Disease.

Sources:

  • L2 Bio, LLC
  • Mukesh Kumar, PhD, Regulatory Advisor for L2 Bio
  • Vince Liguori, CEO of L2 Bio
  • Thom Lobe, MD, FFARM, ABAARM, JD, Professor of Pediatric Surgery University of IL at Chicago